— Know what they know.
Not Investment Advice

LBRX NASDAQ

LB Pharmaceuticals Inc Common Stock
1W: -3.3% 1M: +4.6% 3M: +1.6% YTD: +93.9% 1Y: +148.2%
$39.64
+0.30 (+0.76%)
After Hours: $43.55 (+3.91, +9.85%)
Weekly Expected Move ±8.8%
$32 $35 $39 $42 $46
NASDAQ · Healthcare · Biotechnology · Tech Score Buy · Power 62 · $1.3B mcap · 24M float · 1.56% daily turnover · Short 72% of daily vol
Credit Risk of going bust: lower than 80% of companies Debt: 0.4% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99.9%), LB Pharmaceuticals Inc Common Stock would be worth roughly what it owes.
Total debt $5.2M against a stock market value of $1.27B.
Distance to default 9.69 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $2.6M (short-term plus half of long-term), stock volatility 62.4%; Altman Z'' 14.47. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

NO EDGE
37.6 / 100
NoneWeakNarrowWide
Primary source: Switching Costs  ·  ROIC: -768.9%
Cost Advantage
33
Intangibles
25
Switching Cost
60
Network Effect
43
Scale
22
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. LBRX has No discernible competitive edge (37.6/100). The business operates without significant structural advantages. The primary source of advantage is Switching Costs. Negative ROIC of -768.9% indicates the company is currently destroying value, though this may reflect a growth investment phase.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$35
Low
$59
Avg Target
$80
High
Based on 7 analysts since Aug 11, 2026 earnings
Analyst Recommendations
Strong Buy: 0Buy: 3Hold: 1Sell: 0Strong Sell: 0
Rating Summary
ConsensusBuy
Avg Target$61.63
Analysts8
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-10-09 Canaccord Genuity Sumant Kulkarni Initiated $65 — +87.8% $34.61
2026-10-05 Guggenheim — Initiated $80 — +131.1% $34.62
2026-10-05 Roth Capital — $37 $35 -2 -2.6% $35.95
2026-10-02 Needham — Initiated $68 — +82.4% $37.28
2026-08-24 H.C. Wainwright Raghuram Selvaraju $45 $60 +15 +26.0% $47.62
2026-08-13 Stifel Nicolaus — $40 $53 +13 +16.8% $45.38
2026-08-12 BMO Capital — $46 $54 +8 +19.1% $45.33
2026-08-03 Piper Sandler Yasmeen Rahimi Initiated $78 — +80.8% $43.14
2026-07-20 BMO Capital — Initiated $46 — +48.9% $30.90
2026-07-07 Wolfe Research Rudy Li Initiated $45 — +34.7% $33.41
2026-05-17 Roth Capital — $31 $37 +6 +24.7% $29.66
2026-04-27 H.C. Wainwright — Initiated $45 — +46.4% $30.73
2026-04-10 Craig-Hallum — Initiated $36 — +45.8% $24.68
2026-03-27 Stifel Nicolaus — $35 $40 +5 +67.8% $23.84
2026-01-09 Roth Capital — Initiated $31 — +49.0% $20.80
2025-12-11 Stifel Nicolaus — $27 $35 +8 +63.9% $21.36
2025-10-06 Leerink Partners — Initiated $34 — +125.9% $15.05
2025-10-06 Stifel Nicolaus — Initiated $27 — +79.4% $15.05

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

C+
Oct 27, 2026
DCF
3
ROE
1
ROA
1
D/E
4
P/E
1
P/B
2
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. LBRX receives an overall rating of C+. Strongest factors: D/E (4/5). Areas of concern: ROE (1/5), ROA (1/5), P/E (1/5), P/B (2/5).
Rating Change History
DateFromTo
2026-10-12 C C+
2026-10-01 C+ C
2026-04-27 C C+
2026-04-01 C+ C
2026-03-27 B- C+
2026-01-14 C- B-

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ — Grade A+
Profitability
—
Balance Sheet
85
Earnings Quality
68
Growth
—
Value
38
Momentum
—
Safety
100
Cash Flow
—

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
19.53
Safe Zone
Piotroski F-Score
2/9
✗ ✗ ✗ ✓ ✗ ✗ ✓ ✗ ✗
Beneish M-Score
—
—
Ohlson O-Score
-3.94
Bankruptcy prob: 1.9%
Low Risk
Credit Rating
A+
Score: 75.6/100
Earnings Quality
—
OCF/NI: 0.96x
Accruals: -0.9%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. LBRX scores 19.53, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. LBRX scores 2/9, suggesting weak financial fundamentals — the company fails the majority of these accounting tests. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. LBRX's implied 1.9% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. LBRX receives an estimated rating of A+ (score: 75.6/100).

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
-13.38x
PEG
-0.08x
P/S
0.00x
P/B
3.60x
P/FCF
-11.81x
P/OCF
—
EV/EBITDA
-7.48x
EV/Revenue
—
EV/EBIT
-7.45x
EV/FCF
-7.92x
Earnings Yield
-8.76%
FCF Yield
-8.47%
Shareholder Yield
0.00%
Graham Number
—
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. LBRX currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
1.000
NI / EBT
×
Interest Burden
0.974
EBT / EBIT
×
EBIT Margin
—
EBIT / Rev
×
Asset Turnover
0.000
Rev / Assets
×
Equity Multiplier
1.088
Assets / Equity
=
ROE
-25.8%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. LBRX's ROE of -25.8% is driven by A tax burden ratio of 1.00 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate
0.00%
Fair P/E
8.50x
Intrinsic Value
—
Price/Value
—
Margin of Safety
—
Premium
—

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 284 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$39.64
Median 1Y
$68.79
5th Pctile
$25.01
95th Pctile
$189.49
Ann. Volatility
61.4%
Analyst Target
$61.63
25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
Heather Turner
Chief Executive Officer
$568,750 $— $11,884,985
Anna Eramo
Chief Medical Officer
$414,063 $— $2,376,939
Gad Soffer
$— $— $—

CEO Pay Ratio

24:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $11,884,985
Avg Employee Cost (SGA/emp): $494,037
Employees: 27

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
27
Revenue / Employee
—
Profit / Employee
$-933,519
NI: $-25,205,000
SGA / Employee
$494,037
Avg labor cost proxy
R&D / Employee
$620,148
Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q3'25 Q4'25 Q1'26 Q2'26 Current
ROE -1.1% -5.0% -9.0% -25.8% -25.78%
ROA -1.1% -4.8% -8.7% -23.7% -23.69%
ROIC 7.0% -1.6% -2.0% -7.7% -7.69%
ROCE -1.1% -4.9% -8.9% -26.0% -26.02%
Gross Margin — — — — —
Operating Margin — — — — —
Net Margin — — — — —
EBITDA Margin — — — — —
FCF Margin — — — — —
OCF Margin — — — — —
ROIC Economic snapshot only -22.26%
Cash ROA snapshot only -22.78%
Cash ROIC snapshot only -8.43%
CROIC snapshot only -8.47%
Valuation
Metric Trend Q3'25 Q4'25 Q1'26 Q2'26 Current
P/E Ratio -112.34 -37.47 -20.43 -11.42 -13.377
P/S Ratio — — — — 0.000
P/B Ratio 1.29 1.87 1.84 2.94 3.603
P/FCF -118.43 -26.17 -15.53 -11.81 -11.811
P/OCF — — — — —
EV/EBITDA -25.51 -18.27 -9.88 -7.48 -7.481
EV/Revenue — — — — —
EV/EBIT -24.93 -18.07 -9.81 -7.45 -7.451
EV/FCF -26.29 -12.62 -7.46 -7.92 -7.916
Earnings Yield -0.9% -2.7% -4.9% -8.8% -8.76%
FCF Yield -0.8% -3.8% -6.4% -8.5% -8.47%
Price/Tangible Book snapshot only 2.944
Shareholder Yield snapshot only 0.00%
Leverage & Solvency
Metric Trend Q3'25 Q4'25 Q1'26 Q2'26 Current
Current Ratio 47.60 41.44 35.68 15.08 15.078
Quick Ratio 47.60 41.44 35.68 15.08 15.078
Debt/Equity 0.01 0.01 0.01 0.02 0.016
Net Debt/Equity -1.00 -0.97 -0.96 -0.97 -0.971
Debt/Assets 0.01 0.01 0.01 0.01 0.014
Debt/EBITDA -1.05 -0.24 -0.10 -0.06 -0.060
Net Debt/EBITDA 89.44 19.62 10.70 3.68 3.680
Interest Coverage — — — — —
Equity Multiplier 1.03 1.04 1.04 1.09 1.088
Cash Ratio snapshot only 13.911
Cash to Debt snapshot only 62.831
FCF to Debt snapshot only -15.877
Defensive Interval snapshot only 1261.1 days
Efficiency & Turnover
Metric Trend Q3'25 Q4'25 Q1'26 Q2'26 Current
Asset Turnover 0.00 0.00 0.00 0.00 0.000
Inventory Turnover — — — — —
Receivables Turnover — — — — —
Payables Turnover 0.03 0.04 0.02 0.07 0.074
DSO — — — — —
DIO 0 0 0 0 0.0 days
DPO 11671 9585 15941 4901 4900.8 days
Cash Conversion Cycle — — — — —
Fixed Asset Turnover snapshot only 0.000
Cash Velocity snapshot only 0.000
Growth Quality
Metric Trend Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue Stability — — — — —
Earnings Stability — — — — —
Margin Stability — — — — —
Rev. Growth Consistency 0.00 0.00 0.00 0.00 0.000
Earn. Growth Consistency 0.00 0.00 0.00 0.00 0.000
FCF Positive Streak 0 0 0 0 0
Earnings Persistence — — — — —
Earnings Smoothness — — — — —
ROE Trend — — — — —
Gross Margin Trend — — — — —
FCF Margin Trend — — — — —
Sustainable Growth Rate — — — — —
Internal Growth Rate — — — — —
Cash Flow Quality
Metric Trend Q3'25 Q4'25 Q1'26 Q2'26 Current
OCF/Net Income 0.95 1.43 1.31 0.96 0.962
FCF/OCF 1.00 1.00 1.00 1.01 1.005
FCF/Net Income snapshot only 0.967
CapEx/Revenue — — — — —
CapEx/Depreciation snapshot only 1.261
Accruals Ratio -0.00 0.02 0.03 -0.01 -0.009
Sloan Accruals snapshot only 0.010
Cash Flow Adequacy snapshot only -189.414
Dividends & Buybacks
Metric Trend Q3'25 Q4'25 Q1'26 Q2'26 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio — — — — —
FCF Payout Ratio — — — — —
Total Payout Ratio — — — — —
Div. Increase Streak — — — — —
Chowder Number — — — — —
Buyback Yield 0.0% 0.0% 0.0% 0.0% 0.00%
Net Buyback Yield -0.1% -0.2% -13.3% -9.5% -9.50%
Total Shareholder Return -0.1% -0.2% -13.3% -9.5% -9.50%
DuPont Factors
Metric Trend Q3'25 Q4'25 Q1'26 Q2'26 Current
Tax Burden (NI/EBT) 1.00 1.00 1.00 1.00 1.000
Interest Burden (EBT/EBIT) 1.00 1.00 1.00 0.97 0.974
EBIT Margin — — — — —
Asset Turnover 0.00 0.00 0.00 0.00 0.000
Equity Multiplier 1.03 1.04 1.04 1.09 1.088
Per Share
Metric Trend Q3'25 Q4'25 Q1'26 Q2'26 Current
EPS (Diluted TTM) $-0.14 $-0.59 $-1.21 $-2.84 $-2.84
Book Value/Share $12.26 $11.91 $13.41 $11.03 $11.03
Tangible Book/Share $12.26 $11.91 $13.41 $11.03 $11.03
Revenue/Share $0.00 $0.00 $0.00 $0.00 $0.00
FCF/Share $-0.13 $-0.85 $-1.59 $-2.75 $-2.75
OCF/Share $-0.13 $-0.85 $-1.59 $-2.73 $-2.73
Cash/Share $12.43 $11.67 $12.95 $10.88 $10.88
EBITDA/Share $-0.14 $-0.59 $-1.20 $-2.91 $-2.91
Debt/Share $0.14 $0.14 $0.12 $0.17 $0.17
Net Debt/Share $-12.29 $-11.53 $-12.82 $-10.70 $-10.70
Academic Models
Metric Trend Q3'25 Q4'25 Q1'26 Q2'26 Current
Altman Z-Score — — — — 19.525
Altman Z-Prime snapshot only 37.581
Piotroski F-Score 2 1 1 2 2
Beneish M-Score — — — — —
Ohlson O-Score snapshot only -3.937
ROIC (Greenblatt) snapshot only -26.08%
Net-Net WC snapshot only $10.82
EVA snapshot only $-76134050.00
Credit
Metric Trend Q3'25 Q4'25 Q1'26 Q2'26 Current
Credit Rating snapshot only A+
Credit Score 75.87 75.70 75.71 75.58 75.581
Credit Grade snapshot only 5
Implied Spread (bps) snapshot only 125.000
Industry Credit Rank snapshot only 76
Sector Credit Rank snapshot only 70

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms